Abstract
Background Rituximab and ocrelizumab target the same CD20 receptor. Rituximab is off-patent and prescribed off-label; ocrelizumab is licensed and patent-protected. Whether the resulting differences in utilization and cost reflect clinical value or regulatory structure has not been examined.
Objective To determine whether utilization and cost of B-cell depleting therapy across six health systems track regulatory approval status more closely than comparative effectiveness.
Methods We examined rituximab and ocrelizumab utilization and cost in Sweden, France, Germany, the United Kingdom, Italy and the United States (2016–2024). Costs were drawn from published national sources on a consistent ex-factory basis. Utilization was registry-measured for Sweden, France and Germany, measured from national claims for the United States, and estimated from indirect data for the United Kingdom and Italy. Weighted annual costs per patient on B-cell depleting therapy were modeled by Monte Carlo simulation (10,000 iterations).
Results Rituximab constituted the near-totality of B-cell depleting therapy in Sweden but 2.3% to 18.7% of use in the other five systems. Mean annual cost per patient ranged from $3,014 (Sweden) to $52,506 (United States), a 17-fold difference, with the four other European systems between $18,140 and $26,262. Adopting Sweden’s utilization pattern was associated with modeled five-year per-patient differences in drug acquisition cost of $76,000 to $248,000.
Conclusion Utilization and cost align more closely with regulatory approval status than with available effectiveness data. International reference pricing acts on the price of the licensed agent but leaves intact the regulatory asymmetry that determines which agent is prescribed.
Précis Rituximab’s share of anti-CD20 use in multiple sclerosis, and its cost, track national off-label reimbursement rules rather than comparative effectiveness, across six high-income health systems.
Highlights What is already known. Rituximab and ocrelizumab deplete the same B-cell population, and a phase 3 randomized trial has now reported rituximab non-inferior to ocrelizumab on the primary radiological endpoint. Rituximab is off-patent and prescribed off-label; ocrelizumab is licensed and patent-protected. Whether the large international differences in which agent is used, and at what cost, reflect clinical value or regulatory structure had not been examined.
What this study adds. Across Sweden, France, Germany, the United Kingdom, Italy and the United States, rituximab’s share of anti-CD20 use ranged from 96% to 2.3% and mean annual cost per treated patient from $3,014 to $52,506. Because United States and Swedish ex-factory prices differ by the same 2.80-fold for both drugs, the cost gap separates exactly into a price component and a utilization component.
What it means for decision making. Utilization tracked national off-label reimbursement rules rather than comparative effectiveness or price. Adopting Sweden’s utilization pattern corresponds to modeled five-year drug-acquisition differences of $76,000 to $248,000 per patient. International reference pricing acts on the price of the licensed agent and leaves the regulatory asymmetry intact, so measures that change which agent may be reimbursed, such as treatment compendia and off-label outcome tracking, are the operative levers.
Competing Interest Statement
N.S.S. has served as a consultant to Genentech and Amgen. T.A. declares no competing interests.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study used ONLY data that were openly available to the public before the study was initiated. All utilization and cost inputs were taken from published peer-reviewed articles, publicly posted national multiple sclerosis registry annual reports, and publicly available national drug price schedules and reimbursement tariff listings. Every source is cited in full in the manuscript reference list and in the supplementary appendix, with the originating organization and publication year given for each. No dataset was obtained by request, application, screening, or registration, and no individual-level or patient-level data were used.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data supporting this study are drawn from published sources, national registry reports, and publicly available price schedules, each cited in the manuscript and supplementary appendix. No individual patient-level data were used. Simulation code and input parameters are described in the supplementary appendix; the Monte Carlo model used 10,000 iterations with seed 20260806 and is reproducible from the parameters reported.
